Levofloxacin: role and place in the treatment of infections of the lower respiratorytracts


如何引用文章

全文:

参考

  1. Fish D. N., Chow А. Т. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 1997; 32: 101 - 119.
  2. Drlica K., Zhao X. DNA gyrase, topoisomerase IV, and the 4- quinolones. Microbiol. Mol. Biol. Rev. 1997; 61: 377-392.
  3. Hawkey P. M. Mechanisms of quinolone action and microbial response. J. Antimicrob. Chemother. 2003; 51 (suppl. SI): 29-35.
  4. Hooper D. С. Mechanisms of fluoroquinolone resistance. Drug Resistance Updat. 1999; 2: 38-55.
  5. Hoshino K., Kitamura A., Morrissey I. et al. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob. Agents Chemother. 1994; 38: 2623-2627.
  6. Langtry H. D., Lamb H., M. Levofloxacin: Its use in infections of respiratory tract, skin, soft tissues and urinary tract. Drugs 1998; 56: 487-515.
  7. National Committee for Clinical Laboratory Standars. Perfomance standards for antimicrobial susceptibility testing: twelfth informational supplement, v. 22 Wayne (PA); 2002. NCCLS document M100-S12.
  8. Montanari M. P., Mingoia M., Marchetti F. et al. In vitro activity of levofloxacin against Gram-positive bacteria. Chemotherapy 1999; 45: 411-417.
  9. Felmingam D., Reinert R. R., Hikarata Y., Rodlqff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin.J. Antimicrob. Chemother. 2002; 50 (suppl. SI): 25-37.
  10. Thornsberry C., Sahm D. F., Kelly L. J. et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin. Infect. Dis. 2002; (suppl. 1): 4-16.
  11. Amsden G. W., Amankwa K. Pneumococcal resistance: The treatment challenge. Ann. Pharmacother. 2001; 35(4): 480- 488.
  12. Brown P. D., Lerner S. A. Community-acquired pneumonia. Lancet L998; 352: 1295-1302.
  13. Blosser-Middleton R. S., Sahm D. F., Karlowsky J. A. et al. Longitudinal analysis of antimicrobial susceptibility among Streptococcus pneumoniae in 13 countries from 1997 to 2002. In: Proceedings of 42,1<i Interscience conference on antimicrobial agents and Chemotherapy (ICAAC), 2002 Sept. 27-30. San Diego; 2002. abstr. C2-1625.
  14. Козлов Р. С., Кречикова О. И., Сивая О. В. и др. Антимикробная резистентность Streptococcus pneumoniae в России: результаты проспективного многоцентрового исследования (фаза А проекта ПеГАС-1). Клин, микробиол. и антимикроб. химиотер. 2002; 4 (3): 267-277.
  15. Jones R. N.. Сгосо М. А. Т., Pfaller M. A. et al. Antimicrobial activity evaluations of gatifloxacin, a new fluoroquinolone: contemporary pathogen results from a global antimicrobial resistance surveillance program (SENTRY, 1997). Clin. Microbiol. Infect. 1999; 5 (9): 540-546.
  16. Schulin Т., Wennersten C., Ferraro M. et al. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob. Agents Chemother. 1998; 42:1520-1523.
  17. Critchley I., Jones M. E., Heinze P. et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin. Microbiol. Infect. 2002; 8: 214-221.
  18. Anderson M. I., MacGowan A. P. Development of the quinolones. J. Antimicrob. Chemother. 2003; 51 (suppl. SI): 1 - 11.
  19. Wexler H. M., Molitoris E., Molitoris D. et al. In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections. Antimicrob. Agents Chemother. 1998; 42: 984-986.
  20. Chien S.-C., Rogge M. C., Gilson L. G. et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother, 1997; 41 (10): 2256-2260.
  21. Zee L. J., На/kin В., Lee I. D. et al. Effect of food and sucralfate on levofloxacin after a single oral dose of 500 mg in male and female subjects. In: American Society for Microbiology: Abstracts of the 35th Interscience conference on antimicrobial agents and chemotherapy. 1995 Sept. 17-29. San Francisco; 1995. abstr. N A 40.
  22. Holland M., Chien S., Corrado M. et al. The pharmacokinetic profile of levofloxacin following once- or twice-daily 500 mg administration. In: Proceedings of Fifth International symposium on new quinolones, 1994 Aug. 25-27. Singapore; 1994. A42.
  23. Holland M., Chien S., Corrado M. et al. The pharmacokinetic profile of intravenous levofloxacin following once- or twicedaily administration. In: Proceedings of Fifth International symposium on new quinolones, 1994 Aug 25-27; Singapore; 1994. A68.
  24. LeBel M., Vallee F., Bergeron M. Tissue penetration of ciprofloxacin after single and multiple doses. Antimicrob. Agents Chemother. 1986; 29: 501-505.
  25. Gonzalez M., Moranchel A., Duran S. et al. Multiple-doses pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob. Agents Chemother. 1985; 28: 235-239.
  26. Stass H., Dalhoff A., Kubitza D. et al. Pharmacokinetics, safety and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents Chemother. 1998; 42: 2060-2065.
  27. Stass H., Kubitza D. Basic pharmacokinetics of moxifloxacin. Drugs 1999; 58 (suppl. 2): 225-226.
  28. Stass H., Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.J. Antimicrob. Chemother. 1999; 43: 83-90.
  29. Keller I., Lubasch A., Rau M. et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin after a single in healthy volunteers. In: 39"' Interscience conference on antimicrobial agents and chemotherapy; 1999 Sept. 26-29. San Francisco; 1999. abstr. 30.
  30. Drusano G. L., Preston S. L., Gotfried M. H. et al. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 2002; 46: 586-589.
  31. Guay D. R. P. Implications of quinolones pharmacocinetic drag interactions. Hosp. Pharm. 1997; 32: 677-690.
  32. Brown P. D. , Lerner S. A. Community-acquired pneumonia. Lancet 1998; 352: 1295-1302.
  33. File T. M. Jr., Segreti J., Dunbar L. et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 1997; 41 (9): 1965- 1972.
  34. Kahn J. В., Weisinger B. A., Olson W. H. et al. Treatment of patients with commmunity-acquired pneumonia at high risk of mortality. In: American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting. New Orleans; 2001. abstr. PI 15.
  35. Carbon C., Ariza H., Rabie W. J. et al. Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mild-to-moderate communitv-acquired pneumonia. Clin. Microbiol. Infect. 1999; 5 (12):"724-732.
  36. Gotfried M. H., Dattani D., Riffer E. et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets with levofloxacin tablets in the treatment of community-acquired pneumonia. Clin. Ther 2002; 24: 736- 751.
  37. Sullivan J. C., McElroy A. D., Honsinger R. W. et al. A doubleblind, randomized study of safety and efficacy: Treating community-acquired pneumonia with once-daily gatifloxacin vs oncedaily levofloxacin. J. Resp. Dis. 1999; 20 (11); 49-59.
  38. Manggunnegoro H., Soeharno W., Rush A. Early switch therapy from intravenous to oral levofloxacin versus intravenous ceftriaxone to oral cefuroxime axetil in the treatment of moderate to severe community-acquired pneumonia. In: Penetration: New challenges for levofloxacin in the fight against infectious diseases. Annual issue 2004. Tokyo: BIOMEDIS; 2004. 29-35.
  39. Yu V. L., Williams R. R., Stout J. E. et al. Levofloxacin is safe and effective in the management of community-acquired pneumonia (CAP) due to Legionella. J. Antimicrob. Chemother. 2001; 47 (suppl. 1): 45.
  40. Sanders К. М., Marras Т., Chan С. К. The use of a respiratory fluoroquinolone (levofloxacin) for community-acquired pneumonia in the immunocompromised. In: the 7"1 International symposium on new quinolones. Edinburgh; 2001. abstr. N. 111.
  41. Ball P. Role of levofloxacin in the treatment of lower respiratory tract infections. In: Penetration: New challenges for levofloxacin in the fight against infectious diseases. Annual Issue 2003. Tokyo: BIOMEDIS; 2003. 22-32.
  42. West M., Boulanger B. R., Fogarty C. et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia. A multicenter, prospective, randomized, open-label study. Clin. Ther. 2003; 25(2): 485-506.
  43. DeAbate С. A., Russell M., McElvaine P. et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respyir. Care 1997; 42 (2): 206-213.
  44. Weiss L. R. Clarithromycin 500 mg b. i. d. versus levofloxacin 500 mg q.d. versus cefuroxime axetil 250 mg b. i. d. in the treatment of acute exacerbations of chronic bronchitis. Am. J. Respir. Crit. Care Med. 2001; 163 (5, suppl.): A930.
  45. Shah P. M., Maesen F. P., Dolmann A. et al. Levofloxacin versus cefuroxime axetil in the treatment of acute bacterial exacerbation of chronic bronchitis', results of a randomized, double-blind study. J. Antimicrob. Chemother, 1999; 43: 529- 539.
  46. Hautamaki D., Kureishi A., Warner J. et al. Five day moxifloxacin compared to 7 day levofloxacin therapy in the treatment of acute exacerbations of chronic bronchitis (AECB).Am. J. Respir. Crit. Care Med. 2001; 163 (5, suppl.): A771.
  47. Amsden G. W., Baird I. M., Simon S., Treadway G. Efficacy and safety'of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003; 123 (3): 772-777.
  48. Masterton R. G., Burley С. J. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int. J. An timicrob. Agents 2001; 18: 503-512.
  49. Marrie T. J., Lau С. Y., Wheeler S. L. et al. A controlled tria of a critical pathway for treatment of community-acquire pneumonia. Community-acquired pneumonia intervention tria assessing levofloxacin. J. A. M. A. 2000; 283: 749-755.
  50. Fine M. J., Auble T. E., Yeoly D. M. et al. A prediction rule tc identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 1997; 336: 243-250.
  51. Richerson M. A., Ambrose P. G, Quintiliani R. et al. Pharmacoeconomic evaluaton of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia. Infect Dis. Clin. Pract. 1998; 7 (5): 227-233.
  52. Schadlich P. K., Huppertz E., Brecht J. G. et al. Levofloxacir versus relevant alternatives in inpatient treatment of community-acquired pneumonia; results of a German economic evaluation. Antiinfect. Drugs Chemother. 1998; 16 (suppl. 1): 62, abstr. N. T105.
  53. Langtry H. D., Lamb H. M. Levofloxacin: Its use in infections of respiratory tract, skin, soft tissues and urinary tract. Drugs 1998; 56: 487-515.
  54. Adelglass J., Jones Т. М., Ruoff G. et al. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. Pharmacotherapy 1998; 18 (6); 1255-1263.
  55. Sydnor Т. А., Корр Е. J., Anthony К. Е. et al. Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults. Ann. Allergy Asthma Immunol, 1998; 80: 357-362.
  56. Davies B. I., Maesen F. P. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in vitro activity. J. Antimicrob. Chemother. 1999; 43 (suppl. C): 83-90.
  57. Lasko B., Lau C., Saint-Pierre С. et al. Efficacy and safety of oral levofloxacin compared with clarythromycin in the treatment of acute sinusitis in adults: a multicentre, double-blind randomized study. J. Int. Med. Res. 1998; 26: 281-291.
  58. Nicodemo A. C., Robledo J. A., Jasovich A. et al. A multicenter, double-blind, randomized study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int.J. Clin. Pract. 1998; 52 (2): 69-74.
  59. Lipsky B. A., Baker С. A. Fluoroquinolone toxicity profiles: a rewiew focusing on new agents. Clin. Infect. Dis. 1999; 28: 352-364.
  60. О'Hare M., Simpson I. N. Levofloxacin: low potential for cardiovascular adverse reactions. Clin. Microbionnfect. 2001; 7 (suppl. 1): 164-165.
  61. Owens R. С. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001; 21: 301-319.
  62. Noel G. J., Abels R., Minton N. et al. Effects of free fluoroquinolones (FQs) on QTc intervals in healthy volunreers. In: Proceedings of 41s1 Interscience conference on antimicrobial agents and chemotherapy. Chicago; 2001. abstr. N. 639a.
  63. Tillotson G., Ball P. Fluoroquinolone safety profiles. - A review. Today's Ther. Trends 2002; 20: 419-435.
  64. Norrby S. R., Petermann W., Willcox P. A. et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand. J. Infect. Dis. 1998; 30 (4): 397-404.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2004

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##